Cochrane系统评价发表状况调查

目的通过统计我国作者Cochrane系统评价（CSR）的发表状况。方法以Cochrane图书馆（2009年1期）发表的系统评价全文和计划书及Cochrane协作网（2009年3月）注册的题目为数据基础，统计分析不同国家发表系统评价全文、计划书和注册题目情况及我国系统评价全文和计划书发表时间、地区和专业分布情况。结果我国发表Cochrane系统评价全文、计划书和注册题目分别位居世界第7、第5和第2位。我国发表的Cochrane系统评价全文和计划书呈逐年稳步增长趋势，但作者地区间发展不平衡。我国涉及Cochrane协作网51个协作组中的47，未涉及的4个组包括有效实践和健康保健组、用户与交流组、方法学评价组和多发性硬化组。结论中国循证医学发展迅速，在CSR制作中具有很大的潜力，然而，尚存在一些问题亟待解决。

Development of China's Evidence-Based Medicine through the Cochrane Systematic Reviews

Objective The purpose of this study, which focuses on the number of the Cochrane Systematic Review＇s （CSR） full texts, protocols and registered titles from Chinese authors, is to show the development of evidencebased medicine （EBM） and promote EBM＇s further development in China. Methods On the basis of The Cochrane Library （Issue 1, 2009） and the Cochrane Collaboration （March 2009） periodicals, we performed statistical analysis of different countries that released CSR＇s full texts, protocols and registered titles, as well as the time, authors and distribution of the CSR＇s full texts, protocols and registered titles in China. Results The publishing rates of the CSR＇s full texts, protocols and registered titles in China ranked the seventh, fifth and second, respectively. Although the number of CSR＇s full texts and protocols showed an increased annual trend in China, the development of area distribution was unbalanced. Moreover, China＇s published articles contained 47 Cochrane collaboration groups, without effective practice and health care groups, consumers and communication groups, and methodology and multiple stenosis groups. Conclusions The current Chinese EBM situation has a great potential in writing CSR. However, there are still many problems that need to be resolved.